Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. - Wikidata - awgldk - TriplyDB

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

http://www.wikidata.org/entity/Q34778011

about

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future Bayesian variable selection in cost-effectiveness analysis.Modulation of autoimmunity with artificial peptides Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.Assessing cost-effectiveness in the management of multiple sclerosis.Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.Costs and quality of life of patients with multiple sclerosis in Europe Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS.Interferon-beta treatment for multiple sclerosis.Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.Quantitative risk-benefit analysis of natalizumab.UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.Multiple sclerosis: relapses, resource use, and costs.Let cost effectiveness models be open to scrutiny Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran.Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy.Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.Replicating Health Economic Models: Firm Foundations or a House of Cards?The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.Cost-effectiveness of natalizumab in multiple sclerosis.The payer's perspective: What is the burden of MS and how should the patient's perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.Assessing the economic challenges posed by orphan drugs: A comment on Drummond et al Pharmacoeconomics and clinical trials in multiple sclerosis: baseline data from the European Union Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom Pharmacoeconomics

P2860

Q22252598-D20F32D4-AC4E-4914-B0FA-7116E27CA8B2 Q28749656-95F80AA8-C0A1-4004-A800-6EFF99BFEC71 Q30651607-36C7F8BD-C5EA-43DE-B33D-ECB23270AA92 Q31037061-60A409ED-9394-43FB-A5BA-BFA9D233496E Q33397837-4881AC44-8149-4128-8949-DFB5AF9BB1C8 Q33859002-2F5F7DA1-5269-4836-BEFD-B020D12836A4 Q34288089-4C09C7D5-724A-4B52-872B-9DCEF8E4E0F6 Q35119597-0FB83954-2FBA-4F72-8C58-F8514B5C27D0 Q35205463-75BBADEF-8642-4AA6-9F29-CE54FB6260A7 Q35906921-48C7811B-9C25-4407-B8B9-97FB24DC3193 Q36142777-A2507A2C-E42A-4BF1-898D-3A4C3C73E970 Q36469022-A688F39F-45EB-4367-8DC2-CA46ACA6F71A Q36699401-D5A3F75F-34FC-474F-A96A-A51337CCAD29 Q36963178-059B844B-E433-4F89-83E7-07F1BF1EE285 Q36968664-0C098E2B-E228-4DCA-A9E7-16F1102362B5 Q37150465-B436C990-5390-429F-B7A5-55D2D5C72315 Q37178959-305D3008-B7D8-4558-9B52-FC7AC9FA1F59 Q37517082-C58E016E-09B8-4DAB-A732-A0045DE7F9B8 Q37519608-33317FE2-A0A8-4138-A48C-F0CDBEB8EEA3 Q38097527-520AB200-97A9-4450-9923-2C7D971627CC Q38103515-5DE99B45-3F37-4824-94E7-208AD2C85110 Q38197076-BA2B95E1-8273-4D3A-8497-F7ED3F1F6548 Q39300217-9606E1B9-1C46-4986-A751-B1530513AC1D Q40226939-7E031BCA-4F33-403A-8970-BA330DECA346 Q40464842-55A2DA29-A8B0-4CA0-89BC-09CC5957D461 Q42566217-29DD7357-22A5-4D17-AB51-823AF59F3A64 Q42905696-51AB5B5D-9D92-4EBC-AB76-F54154662F49 Q43255273-8A737A83-30D6-44FA-A604-1C0936755A03 Q43280735-550CBE25-45BA-4822-9BDD-D86462B19899 Q44670941-CEA4675A-ABB6-412E-9948-639B735D6725 Q46485291-3392AEFC-D4FA-44B0-9E3D-84464A7A93F5 Q47329445-52122A1E-BC23-4A65-9CD4-42E9961CC060 Q51073340-CCFB08EC-7E7F-4B13-9125-4AB5AE7EA288 Q51146514-D5ED0E2D-AEC9-435C-B825-5DADBDB353A5 Q52985191-367E3DA0-1C4D-47C5-9042-AE3D79A99C14 Q53832244-8C193FA4-AB65-4A81-93BC-6FFCCCC938BE Q56018117-E6BE2595-5BE6-44BE-8820-917725270FC8 Q56698309-D4576F01-4115-4BF4-BF91-FE46187EEB8B Q57573402-07563605-431D-4389-9068-61CA901C2BF1 Q57774074-6B455A88-F6AA-4C11-9BD8-93B28180B792

P2860

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

http://www.wikidata.org/entity/Q34778011

description

2003 nî lūn-bûn

@nan

2003 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մարտին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Modelling the cost effectivene ...... atments in multiple sclerosis.

@ast

Modelling the cost effectivene ...... atments in multiple sclerosis.

@en

Modelling the cost effectivene ...... atments in multiple sclerosis.

@nl

type

label

Modelling the cost effectivene ...... atments in multiple sclerosis.

@ast

Modelling the cost effectivene ...... atments in multiple sclerosis.

@en

Modelling the cost effectivene ...... atments in multiple sclerosis.

@nl

prefLabel

Modelling the cost effectivene ...... atments in multiple sclerosis.

@ast

Modelling the cost effectivene ...... atments in multiple sclerosis.

@en

Modelling the cost effectivene ...... atments in multiple sclerosis.

@nl

P1433

Q34778011-FE8945DD-285C-4218-9F14-77FAD74DFA28

P1476

Q34778011-17668DDA-01A5-44E6-8808-677324775593

P2093

Q34778011-24A62D40-FE83-4AB5-A4F6-8DFE2B1DAFF2

Q34778011-4B4C0403-1F3C-44AE-A8E9-D9F4036EE663

Q34778011-5CE0418C-4618-4DFC-A3A0-6FBC6425D47F

Q34778011-85C7AD8F-D16B-4565-A529-D42B3C64A4B1

Q34778011-86A72DBF-6C2E-4805-AF0B-3DBBCF2E5EC1

Q34778011-8FE49B47-C274-40BD-8E1B-9BA4676355A1

Q34778011-C3115E89-0AD9-467B-A00B-26B34A501579

Q34778011-F220D105-06FA-4B81-BC24-136095062471

P2860

Q34778011-1A2E559C-6064-40D3-997E-9ACAD75AF9BD

Q34778011-1CDEA77D-98FC-45A0-97A7-3AD1A53498BE

Q34778011-235C6729-FFE9-4DEC-A34B-62551B44D27D

Q34778011-34022F6C-05E7-4EA3-B6F8-2060F03D5D08

Q34778011-5816B85E-C29E-48C4-8674-E8F771492501

Q34778011-845BD7D6-B7A1-4277-88FE-3B5D17390806

Q34778011-A39BA7C8-756D-441C-833F-730F19011F7E

Q34778011-B598EB75-B630-4F20-98EF-C4538A4BC170

Q34778011-BD7E021D-2D04-47D1-92F6-238B3A4428DA

Q34778011-D1E34E9D-2DF7-493A-A6F6-6000B36F2613

P304

Q34778011-57563F23-4CD9-4649-88E0-C8E95455815A

P31

Q34778011-DD5642B2-7EC7-462B-BCD0-63AAB5C9C584

P356

Q34778011-69371F8C-9C58-4BCD-B444-57AB6827E4F2

P407

Q34778011-003C3D3A-9DF7-45D9-98D9-1BFCBC34821B

P433

Q34778011-E4A325DA-61A8-46A5-8418-9DB460BE757D

P478

Q34778011-4D8B80A2-8555-483E-8ECD-3FDFB3F496A3

P50

Q34778011-E4214360-BD1D-4C3B-8B23-23EE6C230504

P577

Q34778011-2FE1F7F8-E175-4A34-A66E-D4D662C5394F

P5875

Q34778011-A433967A-0CD0-49E9-AA59-4E26EF2B1449

P698

Q34778011-D9466287-3027-4D7B-8240-539772A1978C

P921

Q34778011-EBB9310E-647D-416B-B9F3-00A1986205E3

P932

Q34778011-16BC4BC7-8935-456C-B0A9-460F1C990134

P356

BMJ.326.7388.522

P1433

P1476

Modelling the cost effectivene ...... eatments in multiple sclerosis

@en

P2093

Chris McCabe

http://www.w3.org/2001/XMLSchema#string

Cost Effectiveness of Multiple Sclerosis Therapies Study Group

http://www.w3.org/2001/XMLSchema#string

David H Miller

http://www.w3.org/2001/XMLSchema#string

Jim Chilcott

http://www.w3.org/2001/XMLSchema#string

Karl Claxton

http://www.w3.org/2001/XMLSchema#string

Keith Abrams

http://www.w3.org/2001/XMLSchema#string

Nicola J Cooper

http://www.w3.org/2001/XMLSchema#string

Paul Tappenden

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.

Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980.

Competing interests in multiple sclerosis research.

P304

522; discussion 522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.326.7388.522

http://www.w3.org/2001/XMLSchema#string

P407

P433

7388

http://www.w3.org/2001/XMLSchema#string

P478

326

http://www.w3.org/2001/XMLSchema#string

P50

Anthony O'Hagan

P577

2003-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10867544

http://www.w3.org/2001/XMLSchema#string

P698

12623909

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

150460

http://www.w3.org/2001/XMLSchema#string